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Objective: Therapies for chronic kidney disease have changed greatly over the last decade. The aim of this
study was to examine the changes in the clinical characteristics and carotid atherosclerosis of patients
with end-stage kidney disease (ESKD) over the last 9 years.
Methods: A cross-sectional study of 150 consecutive patients with ESKD who had initiated maintenance
dialysis between January 2005 and December 2013 was conducted. The patients' mean age was 68 ± 13
years. The group comprised 73% men, and 63% of the patients had diabetic nephropathy. The carotid
artery-intima media thicknesses and the plaque scores (PS) were measured using carotid artery ultra-
sonography within 3 months of dialysis initiation. Changes in the patients' carotid atherosclerosis and
clinical characteristics over the years were examined by categorizing the patients into 3 groups repre-
senting 3-year intervals based on when dialysis was initiated.
Results: The PS declined from 12.8 to 5.4 (P ¼ 0.001). Low-density lipoprotein cholesterol (LDL-C) and
non-high-density lipoprotein cholesterol levels declined over the 9-year period (P ¼ 0.005 and P ¼ 0.006,
respectively), and the ratio of statin users increased markedly from 24% to 54% (P ¼ 0.001). Univariate
regression analysis identiﬁed a positive correlation between the PS and LDL-C (r ¼ 0.281; P ¼ 0.01), and a
strong positive correlationwas found between the PS and LDL-C after adjusting for various risk factors for
atherosclerosis.
Conclusion: Carotid atherosclerosis in patients with ESKD has decreased over the past 9 years, which may
be a consequence of improvements in dyslipidemia management.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It has been suggested that atherosclerosis progression acceler-
ates during the conservative phase of chronic kidney disease (CKD).
Shoji et al. demonstrated that the carotid artery-intima media
thickness (CA-IMT), an early lesion of atherosclerosis measured by
carotid artery ultrasonography, showed a signiﬁcantly higher value
in patients in the conservative phase of CKD compared with the
general population. Importantly, there was little difference in the
CA-IMT between patients receiving dialysis and those in the con-
servative phase of CKD, which demonstrates that atherosclerosis
has already developed before dialysis begins [1]. A strong rela-
tionship has been reported between the severity of CA-IMT andakawa), thayashi0803@gmail.
a), jokinobuhiko@gmail.com
Ireland Ltd. This is an open accessatherosclerotic cardiovascular disease (CVD) development in pa-
tients in the conservative phase of CKD [2]. CVD onset increases as
renal dysfunction deteriorates [3,4]. Therefore, to improve the
prognosis of patients with CKD, atherosclerosis progression must
be prevented from an early stage of the disease.
The involvement of non-traditional risk factors for atheroscle-
rosis that are speciﬁc to CKD, including chronic inﬂammation,
malnutrition, and metabolic disturbances associated with calcium
and phosphorus, tends to be regarded as the involvement of factors
underlying atherosclerosis development and progression of
atherosclerosis in patients with CKD. However, the classical risk
factors for atherosclerosis, including hypertension and dyslipide-
mia, are also strongly involved in atherosclerosis progression in
patients with CKD [5e7]. Statins and renin-angiotensin-
aldosterone system (RAS) inhibitors prevent atherosclerosis pro-
gression in the general population [6], and RAS inhibitors also have
renoprotective effects. Recently, it has been reported that using
statins to manage dyslipidemia reduces proteinuria and retards thearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Schema of the study's design. ESKD, end-stage kidney disease.
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sure control, mainly using RAS inhibitors, lifestyle modiﬁcations,
and using statins for lipid management will slow the progression of
renal dysfunction and prevent the progression of atherosclerosis.
Consequently, some international guidelines strongly recommend
the use of these therapies [8e10]. However, we do not know the
extent of the effect, how patients' clinical characteristics have been
altered by these changes, and what the favorable effects have been
on atherosclerosis.
A strong relationship exists between the ﬁndings of carotid ar-
tery ultrasonography and CVD. In the general population, the CA-
IMT, determined by carotid artery ultrasonography, and the
severity of the plaque score (PS) are related to complications
associated with stroke or coronary artery disease (CAD) [11e15].
Similarly, some studies of patients with CKD have also reported that
ﬁndings from carotid artery ultrasonography are useful for pre-
dicting CVD [16e18]. Carotid artery ultrasonography, which can be
performed non-invasively, is useful for evaluating atherosclerotic
lesions and predicting CVD complications in patients with CKD.
We hypothesized that recent changes in CKD management have
improved atherosclerosis. Thus, a study to examine the changes in
carotid atherosclerosis at the initiation of dialysis in parallel with
the changes in patients' clinical characteristics, the changes in
atherosclerosis risk factors, and the changes in pharmacotherapy
over the past decade was conducted.
2. Methods
2.1. Study design and patients
A retrospective cross-sectional comparative study by era that
involved 284 consecutive patients who started maintenance dial-
ysis for end-stage kidney disease (ESKD) at the Toho University
Ohashi Medical Center between January 2005 and December 2013
was conducted. Two of the exclusion criteria (1, death within 3
months of starting dialysis and 2, ESKD due to acute renal impair-
ment) led to 2 patients and 25 patients, respectively, being
excluded from the study, and the remaining 257 patients were
included in the study. Of these patients, 107 had not undergone
carotid artery ultrasonography. Consequently, 150 patients were
divided into 3 groups that represented 3-year intervals, which were
based on the day of dialysis initiation, and their carotid artery ul-
trasonography ﬁndings were compared (Fig. 1). There was some
concern that a selection bias may have been introduced that related
to the characteristics of the patients who did and did not undergo
carotid artery ultrasonography. Therefore, to investigate the val-
idity of the study, the 257 patients were divided into 2 groups ac-
cording to whether they had undergone carotid artery
ultrasonography, and their characteristics were compared before
starting the main analysis. The sample size for the retrospective
data collection was not pre-speciﬁed.
The ethics committee at the Toho University Ohashi Medical
Center approved the study protocol [Approval number, 13e52,
13e61]. Since this was a retrospective, observational study, the
need for consent for individual patients was waived; however, a
notice about the start of this study and that the patients could
express their objections to the use of their data was posted.
2.2. Collection of data
Clinical information was collected from each patient to deter-
mine age, sex, smoking history, diseases underlying their kidney
disease, treatments taken during the conservative phase of the
kidney disease, and disease history. Blood pressure was measured
immediately before the ﬁrst dialysis session in the supine position,and a blood sample taken immediately before the ﬁrst dialysis
session was analyzed. Serum calcium (Ca) was corrected using the
following equation: corrected Ca ¼ measured Ca (mg/
dL) þ (4  measured albumin [g/dL]). The estimated glomerular
ﬁltration rate (eGFR) was calculated using the following equation:
eGFR (mL/min/1.73 m2) ¼ 194  Cr  1.094  age  0.287
(women 0.739) [19]. Bodymass indices were calculated as weight
(kg)/(height [m])2. HbA1c was recorded as the National Glyco-
hemoglobin Standardization Program (NGSP) value.
2.3. Deﬁnitions of complications
CAD was deﬁned as a history of myocardial infarction, angina
pectoris, or coronary revascularization therapy. Patients were also
deﬁned as having complications associated with CAD if they had
signiﬁcant stenotic lesions that were observed on coronary arteri-
ography, or if ﬁxed defects or irreversible defects were observed
using stress myocardial scintigraphy at the initiation of dialysis.
Patients who had been diagnosed with peripheral artery disease
(PAD) and had undergone catheterization or bypass graft surgery,
or those who had a history of amputation for ischemic lower ex-
tremities were deﬁned as patients with PAD. Patients diagnosed
with cerebral hemorrhage or cerebral embolism and who had prior
treatment for these conditions were deﬁned as patients with
stroke.
2.4. Carotid artery ultrasonography
Carotid artery ultrasonographywas performed at the time of dry
weight after dialysis or on a day that the patients did not undergo
dialysis. Carotid atherosclerosis was evaluated using the mean CA-
IMT (mCA-IMT) of the common carotid artery and the PS. An
experienced clinical laboratory technician evaluated the carotid
artery with a 7.5-MHz linear probe and an Aplio XV, Aplio XG, or a
Xario ultrasonography system (Toshiba Medical Systems Corpora-
tion, Tokyo, Japan), using the B mode and a pulsed Doppler system.
The patients were examined in the supine position without a pil-
low, with their necks tilted slightly away from the carotid artery
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segment of the carotid artery that could be observed using short-
axis imaging was scanned from the proximal (heart) side towards
the distal (head) side to conﬁrm the blood vessel's course and the
plaque locations. Then, the long-axis images of the blood vessel
were produced in parallel to the probe, as much as possible. Images
of the distal common carotid artery bifurcation and the internal
carotid artery bifurcation were obtained for all of the patients as
recommended by the American Society of Echocardiography Ca-
rotid Intima-Media Thickness Task Force [20]. The intima media
thicknesses of at least 3 sites, each separated by at least 1 cm from
other segments of the common carotid artery, were measured, and
the mCA-IMT was obtained. When plaques were present in the
individual segments, the mean thicknesses of the plaques were
added to the CA-IMT measurement.
A CA-IMT of at least 1.1 mmwas deﬁned as a plaque, and the PS
was deﬁned as the sum of the thickest CA-IMTs in individual seg-
ments of the bilateral carotid arteries. As shown in Fig. 2, Segment 1
was deﬁned as the internal carotid artery (ICA) segment 15 mm
distal from the common carotid artery (CCA) bifurcation (Bif).
Segment 2 (S2) was deﬁned as the CCA/ICA segment 15 mm
proximal from the Bif. Segment 3 (S3) was deﬁned as the CCA
segment 30 mm proximal to S2. Segment 4 (S4) was deﬁned as the
CCA segment 30 mm proximal to S3. When determining the PS,
plaque length was not considered.
2.5. Statistical analyses
Data with normal distributions are expressed as the
means ± standard deviations (SD). The data for parameters that did
not have normal distributions are presented as the medians and
interquartile ranges. The groups were evaluated using the c2 test,
analysis of variance, and the KruskaleWallis test. P values <0.05
were considered signiﬁcant. Trends over the 9-year period were
analyzed using the JonckheereeTerpstra test. Factors associated
with the evaluation items of carotid artery ultrasonography were
analyzed using univariate and multivariate linear regression ana-
lyses. All statistical analyses were performed using IBM® SPSS®
software version 20 (IBM Corporation, Armonk, NY, USA).
3. Results
3.1. Comparisons between the patients who did and did not
undergo carotid artery ultrasonography
Of the 257 patients, 107 (41.6%) did not undergo carotid artery
ultrasonography. To understand the trends in carotid arteryFig. 2. Schema of plaque score calculation.sclerosis over the years and to conﬁrm that any selection bias was
minimal, the patients' characteristics were compared and exam-
ined according to the era and in relation to whether the patients
had undergone carotid artery ultrasonography. No signiﬁcant dif-
ferences were found between the groups in Era 1; however, in Era 2,
the ratio of men and the stroke and obstructive arteriosclerosis
prevalence rates were higher in the group that had undergone ul-
trasonography than in the group that had not undergone ultraso-
nography (Table 1). In Era 3, the group that underwent
ultrasonography showed a higher systolic blood pressure and a
higher prevalence of diabetes mellitus compared with the group
that did not undergo ultrasonography. In the latter half of the 9-
year period analyzed, carotid artery ultrasonography was per-
formed on patients with high atherosclerosis risks. Based on these
data, we decided to pursue this study to prove our hypothesis;
hence, a primary analysis of the 150 patients who had undergone
carotid artery ultrasonography was performed.
3.2. Patients' baseline characteristics
Table 2 presents the baseline characteristics of the 150 patients
with ESKD who were evaluated for carotid atherosclerosis. The
mean ± SD age of the patients was 68 ± 13 years, and the median
age was 70 years (60e78 years). Men accounted for 73% of the
patients, and 63% of the patients had diabetes mellitus (DM). The
median serum creatinine (Cr) and eGFR values at the initiation of
dialysis were 9.3 mg/dL (7.5e11.7 mg/dL) and 4.5 mL/min/1.73 m2
(3.5e5.9 mL/min/1.73 m2), respectively. The prevalences of CAD
and stroke were 18% and 19%, respectively, and renin-angiotensin
system (RAS) inhibitors and statins were administered to 65% and
39% of the patients, respectively.
3.3. Changes in the patients' baseline characteristics and carotid
arteriosclerosis over the years
The age of the patients increased signiﬁcantly over the years
(P < 0.001); however, with the exception of the lipid proﬁles, the
classical risk factors for atherosclerosis, including diabetes mellitus,
smoking, and blood pressure, did not differ over the years (Table 2).
A marked decreasing trend was apparent for low-density lipopro-
tein cholesterol (LDL-C) (P ¼ 0.005) and non-high-density lipo-
protein cholesterol (non-HDL-C) (P ¼ 0.006) levels. C-reactive
protein levels, a non-traditional risk factor for atherosclerosis,
decreased over the years (P ¼ 0.04), hemoglobin levels increased
markedly over the years (P < 0.001), and serum phosphate levels
increased markedly over the years (P < 0.01). The use of statins
(P ¼ 0.001), b-blockers (P ¼ 0.01), oral hypoglycemic agents (OHA)
(P < 0.03), and AST-120 (P < 0.02) increased over the 9-year period;
however, RAS inhibitor use did not change markedly over the years.
No clear trend in the mCA-IMT was observed; however, the PS
decreased signiﬁcantly from 12.8 to 5.4 (P ¼ 0.01) (Fig. 3). Hence,
the factors that contributed to the PS improvement were examined.
3.4. Factors associated with the PS
Univariate linear regression analysis identiﬁed signiﬁcant posi-
tive correlations between the PS and age, CAD, eGFR, and LDL-C
(Table 3). Signiﬁcant negative correlations existed between dia-
stolic blood pressure and BUN and Cr. A positive correlation be-
tween the PS and antiplatelet medicine use was observed;
however, no correlations were apparent between the PS and other
medicines. Based on the changes in the risk factors over the years
(Table 2) and the investigation of the factors that contributed to the
PS (Table 3), a decrease of LDL-C was considered a key factor
involved in the PS improvement over the years. Therefore,
Table 1
Comparison of baseline characteristics between the 257 ESKD patients with and without B-mode ultrasound examination of the carotid artery in 3 separate eras.
Era 1 Era 2 Era 3
US() US(þ) p US() US(þ) p US() US(þ) p
Total patients No. 58 34 33 45 16 71
Male, (%) 41(71) 24(71) 0.5 16(49) 39(87) *** 9(56) 47(66) 0.3
Age, years 64 65 0.3 68 66 0.2 66 75 0.1
(54e73) (59e74) (55e78) (58e75) (58e82) (63e81)
BMI, kg/m2 19.7 20.7 0.3 21.2 22.0 0.5 20 20.8 0.7
(18.4e21.6) (18.8e23.0) (20.0e23.6) (19.5e23.3) (18e23) (18.6e23.4)
SBP, mmHg 144 160 0.4 160 150 0.8 136 156 *
(130e160) (152e183) (146e170) (140e168) (130e147) (144e178)
DBP, mmHg 70 78 0.1 69 80 0.3 74 76 0.9
(66e80) (70e90) (60e86) (73e91) (62e84) (68e86)
Smoking, (%) 17(29) 9(27) 0.4 8(24) 18(40) 0.1 9(56) 37(52) 0.4
DM, (%) 37(64) 21(62) 0.5 17(52) 27(60) 0.3 4(25) 46(65) **
CAD, (%) 19(33) 6(18) 0.1 4(12) 7(16) 0.4 2(13) 14(20) 0.3
Stroke, (%) 9(16) 7(21) 0.3 1(3) 11(24) ** 0(0) 10(14) 0.1
PAD, (%) 14(25) 13(38) 0.1 2(7) 15(39) ** 2(13) 20(29) 0.1
Statin, (%) 8(14) 8(24) 0.1 8(24) 13(29) 0.4 6(38) 38(54) 0.1
Alb, mg/dL 3.5 3.4 0.2 3.3 3.4 0.5 3.7 3.5 0.8
(3.0e3.8) (3.1e3.7) (2.9e3.4) (3.0e3.7) (3.4e4.3) (3.1e3.8)
Cr, mg/dL 8.2 9.1 0.1 8.4 9.4 0.8 9.3 9.3 0.2
(7.1e10.4) (7.3e12.2) (7.0e10.4) (8.2e11.9) (7.8e10.1) (7.3e11.3)
eGFR, mL/min/1.73 m2 5.2 4.6 0.1 5.2 4.5 0.2 4.7 4.4 0.3
(4.2e5.9) (3.4e6.8) (3.9e6.1) (3.6e5.6) (3.8e5.4) (3.5e5.7)
TC, mg/dL 163 168 0.6 162 154 0.9 164 152 0.6
(142e206) (139e203) (127e209) (133e176) (141e193) (128e176)
HDL-C, mg/dL 45 45 0.1 45 47 0.6 48 46 0.9
(39e53) (40e56) (38e54) (38e55) (40e63) (38e61)
LDL-C, mg/dL 95 107 0.6 92 89 0.1 87 83 0.5
(83e129) (77e135) (74e123) (68e112) (79e115) (67e103)
NHDL-C, mg/dL 121 119 0.1 111 107 0.6 114 102 0.2
(95e168) (94e156) (92e159) (87e127) (99e132) (76e127)
CRP, mg/dL 0.1 0.1 0.8 0.04 0.07 0.4 0.02 0.05 0.4
(0.0e0.1) (0.0e0.1) (0.0e0.2) (0.0e0.2) (0.01e0.05) (0.02e0.14)
Data are means ± SD and medians (interquartile range). BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; DM, Diabetes Mellitus; CAD,
Coronary Artery Disease; PAD, Peripheral Artery Disease; Alb, Albumin; Cr, Creatinine; eGFR, estimated Glomerular Filtration Rate; TC, Total Cholesterol; HDL-C, High Density
Lipoprotein-Cholesterol; LDL-C, Low Density Lipoprotein-Cholesterol; NHDL-C, non-High Density Lipoprotein-Cholesterol; CRP, C-Reactive Protein.
*p＜0.05 **p＜0.01 ***p＜0.001.
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were constructed, and the contribution of LDL-C to the PS was
examined (Table 4).
3.5. Independence of the LDL-C contribution to the PS
Various interrelated factors were adjusted to examine the
relationship between LDL-C and the PS. Model 1 was a univariate
regression analysis between the PS and LDL-C. Model 2 incorpo-
rated renal function, the 3 eras, and the traditional risk factors for
atherosclerosis, including age, sex, smoking history, systolic blood
pressure, and diabetes mellitus. Model 3 included the non-
traditional atherosclerosis risk factors, malnutrition and inﬂam-
mation, in addition to Model 2. Model 4 incorporated the different
values for the lipids in addition to Model 2. Model 5 included fac-
tors associated with calcium and phosphorus metabolic distur-
bances as non-traditional atherosclerosis risk factors. Model 6
incorporated CVD as a complication and the medicines used. Model
7 included factors associated with anemia as a non-traditional
atherosclerosis risk factor. Model 8 included factors associated
with glycemic control as traditional atherosclerosis risk factors.
Model 9 included AST-120. The multivariate linear regression
analysis showed a positive correlation between LDL-C and the PS
after adjusting the individual models for several variables.
3.6. PS and the lipid proﬁle in statin users and non-users in each era
In Era 3, LDL-C and total cholesterol (TC) were signiﬁcantlylower in the statin group, but no other noteworthy differences were
seen (Table 5). Two points should be taken from this table. First, in
all eras, PS tended to be higher in people who used statins than in
those who did not. There is a high likelihood that this is a reﬂection
of the results of statin introduction in patients with more carotid
atherosclerosis. The second is that PS and LDL-C showed a tendency
to decrease together with the era, regardless of whether statins
were used. This ﬁnding suggests the possibility that improvements
in lipids not due to statins may be linked to PS improvements.4. Discussion
4.1. Main ﬁndings of this study
Strict management of blood pressure and dyslipidemia poten-
tially inhibit CKD progression [21e23], and the Japanese guidelines
for the treatment of CKD recommend these approaches [24].
Studies in general populations have revealed that the management
of blood pressure and dyslipidemia inhibits the progression of
atherosclerosis and the onset of cardiovascular events [25], and that
it may be effective at slowing atherosclerosis in CKD patients. In the
present study, the PS at the initiation of dialysis decreased signiﬁ-
cantly over 9 years. Furthermore, LDL-C levels decreased and statin
use increased in the same timeframe. However, regression analysis
showed that there was no correlation between the increase in
statin use and improvements in the PS over the 9-year period, but
there was a correlation between the LDL-C level and the PS
decrease. Other factors thought to contribute to arteriosclerosis
Table 2
Baseline characteristics of the 150 ESKD patients.
Total Era 1 Era 2 Era 3 JonckheereeTerpstra trend test
150 34 45 71
Male, (%) 110(73) 24(71) 39(87) 47(66) 0.2
Age, years 70(60e78) 65(59e74) 66(58e75) 75(63e81) ＜0.001
BMI, kg/m2 21.2(19.2e23.3) 20.7(18.8e23.0) 22.0(19.5e23.3) 20.8(18.6e23.4) 0.1
Smoking, (%) 64(43) 9(27) 18(40) 37(52) 0.1
SBP mmHg 155(144e177) 160(152e183) 150(140e168) 156(144e178) 0.2
DBP mmHg 78(70e89) 78(70e90) 80(73e91) 76(68e86) 0.2
Alb, mg/dL 3.4(3.1e3.7) 3.4(3.1e3.7) 3.4(3.0e3.7) 3.5(3.1e3.8) 0.1
BUN, mg/dL 89(71e103) 96(77e110) 86(71e100) 87(71e99) 0.2
Cr, mg/dL 9.3(7.5e11.7) 9.1(7.3e12.2) 9.4(8.2e11.9) 9.3(7.3e11.3) 0.5
eGFR, mL/min/1.73 m2 4.5(3.5e5.9) 4.6(3.4e6.8) 4.5(3.6e5.6) 4.4(3.5e5.7) 0.1
UA, mg/dL 8.0(6.5e9.3) 7.9(6.5e8.6) 7.5(6.3e8.9) 8.1(6.5e9.9) 0.9
Ca, mg/dL 8.5(7.8e8.9) 8.3(7.2e8.8) 8.3(7.7e8.8) 8.6(8.0e8.9) 0.2
P, mg/dL 6.1(5.2e7.2) 5.9(4.8e6.8) 5.7(5.4e7.1) 6.4(5.6e7.4) 0.01
TC, mg/dL 156(133e182) 168(139e203) 154(133e176) 152(128e176) 0.08
TG, mg/dL 101(80e138) 112(87e145) 94(73e134) 102(82e140) 0.3
HDL-C, mg/dL 47(38e59) 45(40e56) 47(38e55) 46(38e61) 0.2
LDL-C, mg/dL 88(68e113) 107(77e135) 89(68e112) 83(67e103) 0.005
NHDL-C, mg/dL 108(82e134) 119(94e156) 107(87e127) 102(76e127) 0.006
BS, mg/dL 139(112e169) 149(124e181) 136(111e166) 132(104e167) 0.08
HbA1c (NGSP), % 5.4(5.1e5.9) 5.6(5.3e6.0) 5.4(5.2e5.9) 5.4(5.1e5.7) 0.2
GA, % 18.2(15.7e21.2) 22.0(18.1e24.6) 17.6(15.7e21.6) 18.1(15.6e20.0) 0.4
CRP, mg/dL 0.06(0.00e0.15) 0.1(0.0e0.1) 0.07(0.0e0.2) 0.05(0.02e0.14) 0.04
Hb, g/dL 8.8(7.6e9.9) 7.9(6.9e9.1) 8.6(7.4e9.7) 9.1(8.5e10.1) ＜0.001
iPTH, mg/dL 267(191e369) 229(165e447) 262(171e357) 297(206e360) 0.1
mCA-IMT, mm 0.9(0.7e1.1) 0.8(0.7e1.0) 1.0(0.7e1.3) 0.9(0.7e1.1) 0.1
PS 7.8(3.8e13.2) 12.8(3.3e19.9) 8.1(4.4e11.8) 5.4(3.2e12.6) 0.01
DM, (%) 94(63) 21(62) 27(60) 46(65) 0.6
CAD, (%) 27(18) 6(18) 7(16) 14(20) ＜0.001
Stroke, (%) 28(19) 7(21) 11(24) 10(14) 0.2
RASI total, (%) 98(65) 17(50) 33(73) 8(68) 0.2
CCB, (%) 110(73) 24(71) 33(73) 53(75) 0.6
Beta blocker, (%) 40(27) 5(15) 10(22) 25(35) 0.01
Statin, (%) 59(39) 8(24) 13(29) 38(54) 0.001
Aspirin, (%) 49(33) 12(35) 16(36) 21(30) 0.4
ESA, (%) 114(77) 23(68) 36(80) 55(79) 0.3
Phosphate binders, (%) 13(8) 1(3) 7(16) 5(7) 0.9
Vitamin D analogs, (%) 23(15) 7(20) 8(18) 8(11) 0.2
OHA, (%) 16(11) 2(6) 2(4) 12(17) 0.03
Insulin, (%) 39(26) 12(35) 11(24) 16(23) 0.2
AST-120, (%) 27(18) 10(29) 8(20) 8(11) 0.02
Data are means ± SD and medians (interquartile range). BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; Alb, Albumin; Cr, Creatinine; eGFR,
estimated Glomerular Filtration Rate; UA, Uric Acid; Ca, Calcium; P, Phosphate; TC, Total Cholesterol; TG, Triglyceride; HDL-C, High Density Lipoprotein-Cholesterol; LDL-C,
Low Density Lipoprotein-Cholesterol; NHDL-C, non-High Density Lipoprotein-Cholesterol; BS, Blood Sugar; GA, GlycoAlbumin; CRP, C-Reactive Protein; Hb, Hemoglobin;
intactPTH, intact Parathyroid Hormone; mCA-IMT, mean Carotid Artery-Intima Media Thickness; PS, Plaque Score; DM, Diabetes Mellitus; CAD, Coronary Artery Disease; PAD,
Peripheral Artery Disease; RASI, Renin Angiotensin System Inhibitor; CCB, Calcium Channel Blocker; ESA, Erythropoiesis Stimulating Agent; OHA, Oral Hypoglycemic Agent.
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have a clear association with PS. This indicates that changes in CKD
treatment and patients' characteristics in recent years have reduced
LDL-C levels, which, in turn, have improved carotid atherosclerosis.
However, we have to be cautious about discussing direct causal
relationships because this was a cross-sectional study that
compared individual eras.
4.2. Changes in eras and atherosclerotic disease
Studies examining the effects of changes in treatment over the
years, like this study, have been sequentially reported in recent
years. A study of patients managed under the Medicare program in
the United States reported that the stroke incidence rate has
declined over the past 20 years and the use of statins and antihy-
pertensive medicines has increased [26]. Another American study
that analyzed the data of 57,000 patients with diabetes mellitus
reported substantial changes in the complications associated with
type 2 diabetes mellitus from 1990 to 2010, and, in particular, the
incidence of acute myocardial infarction decreased by 70% during
the 20-year period [27]. We recently reported that, over the past 20years, the prevalence of CAD at the initiation of dialysis has
decreased, risk factors have improved, and drug use has increased
[28]. Therefore, it is not surprising that changes in patients' clinical
characteristics and treatments over the years have led to a result
that suggests that improvements in carotid atherosclerosis may
also be seen in patients with CKD.
4.3. LDL-C and carotid atherosclerosis
Many studies have reported on the relationship between LDL-C
levels and the severity of carotid atherosclerosis. Salonen et al.
studied the relationship between the CA-IMT and abnormal lipid
metabolism in 720 healthy men and reported that the CA-IMT in-
creases as the LDL-C level increases [29]. Other studies have re-
ported decreases in LDL-C levels and improvements in carotid
atherosclerosis. John et al. reported that the statin-induced
decrease in LDL-C levels contributed to improvements in carotid
atherosclerosis [30]. In addition, it has been conﬁrmed that carotid
atherosclerosis in patients with CKD is more severe even in the
early stages of kidney disease than in healthy individuals, and that a
positive correlation exists between an increase in the LDL-C level
Fig. 3. Trends in the clinical parameters over the 3 eras. [A] Low-density lipoprotein cholesterol (LDL-C) (P ¼ 0.005 for trend) and [B] non-high-density lipoprotein cholesterol (HDL-
C) (P ¼ 0.006 for trend) levels tend to decrease over the years. [C] The rate of statin use increases over the years (P ¼ 0.001 for trend). [D] Regarding carotid arteriosclerosis, the
plaque score declines markedly from 12.8 to 5.4 (P ¼ 0.01 for trend).
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the carotid artery PS and in LDL-C levels over the years are thought
to be in line with the results of those previously published studies
[29e31].
4.4. Changes in lipid levels and statin use
In this study, reductions in LDL-C levels and increases in statin
use over the years were conﬁrmed. Although it might be natural to
deduce that statin use has led to improvements in dyslipidemia, a
supplementary analysis did not ﬁnd a negative correlation between
statin use and the LDL-C level. Therefore, the reduction in the LDL-C
level over the 9-year period might be associated with lifestyle
improvements rather than therapeutic interventions. In fact, as
shown in Table 5, PS showed a tendency to improve with the era
regardless of whether statins were used. In parallel with this, a
tendency for improvements in LDL-C was seen even in people who
did not use statins. This suggests that lifestyle improvements
contribute to PS improvements more than statin use does. Unfor-
tunately, our database does not contain any parameters associated
with lifestyle; hence, this hypothesis could not be proven. A pub-
lication that describes a decrease in the incidence of stroke [26] also
reports that, over the past 20 years, total cholesterol levels have
decreased from 210 mg/dL to 183 mg/dL and from 230 mg/dL to
206 mg/dL in men and women, respectively. However, the article
did not describe the relationship between statin use and reductionsin cholesterol levels, but this does not necessarily mean that the
relationship does not exist. Furthermore, the study's results help to
corroborate the ﬁndings of the current study.
4.5. Differences between the CA-IMT and the PS
At ﬁrst, we hypothesized that both the CA-IMTand the PS would
decrease equally over the 9-year period. However, while the PS
changed, the CA-IMT did not change. Whereas the CA-IMT repre-
sents the mean thickness of the intima media, the PS scores the
plaques, which are deﬁned as the regions where the CA-IMT is
1.1 mm or thicker. Hence, the CA-IMT is indicative of subclinical
early atherosclerosis, and the PS principally signiﬁes advanced
atherosclerosis, that is, lesions that are more likely to lead to a
cardiovascular event. Some studies that have used carotid artery
ultrasonography report that plaque areas and the PS are more
closely related to the onset of CVD than the CA-IMT [31e33], which
concurs with the description given above. The present study
investigated patients with ESKD inwhom complications associated
with more advanced atherosclerotic lesions would be a concern.
Hence, it is understandable that changes were only observed in the
PS. As described previously, we have reported that the prevalence
CAD at the initiation of dialysis has decreased over the last 20 years
[28]. A study undertaken in Japan reported that the severity of CAD
correlated only with the PS and not with the CA-IMT [33]. Judging
from these results, assessment of PS may be more useful than IMT
Table 3
Univariate linear regression analysis for the factors associated with PS.
Regression coefﬁcient 95% CI p
Lower Upper
Age, years 0.333 0.105 0.284 ＜0.001
Male, (%) 0.007 2.714 2.942 0.9
BMI 0.095 0.444 0.119 0.2
SBP, mmHg 0.084 0.078 0.025 0.3
DBP, mmHg 0.249 0.173 0.037 0.003
Smoking, (%) 0.056 1.646 3.403 0.4
DM, (%) 0.064 1.568 3.593 0.4
CAD, (%) 0.254 1.946 8.243 0.002
Stroke, (%) 0.03 2.61 3.807 0.7
Alb, mg/dL 0.121 4.305 0.637 0.1
BUN, mg/dL 0.190 0.102 0.003 0.04
Cr, mg/dL 0.283 0.948 0.275 ＜0.001
eGFR, mL/min/1.73 m2 0.219 0.222 1.519 0.009
UA, mg/dL 0.069 0.335 0.809 0.4
Ca, mg/dL 0.065 1.545 0.668 0.4
P, mg/dL 0.149 1.291 0.072 0.07
TC, mg/dL 0.115 0.007 0.038 0.1
TG, mg/dL 0.053 0.014 0.026 0.5
HDL-C, mg/dL 0.007 0.082 0.075 0.9
LDL-C, mg/dL 0.281 0.021 0.086 0.001
Non-HDL-C, mg/dL 0.132 0.006 0.045 0.1
BS, mg/dL 0.167 0.003 0.058 0.07
HbA1c, % 0.154 0.456 3.534 0.1
GA, % 0.073 0.151 0.336 0.4
CRP, mg/dL 0.112 1.104 6.048 0.1
Hb, g/dL 0.024 0.626 0.848 0.7
iPTH, mg/dL 0.129 0.007 0.001 0.1
mCA-IMT, mm 0.559 8.383 13.773 ＜0.001
RASI total, (%) 0.119 4.537 0.681 0.1
CCB, (%) 0.067 3.997 1.647 0.4
Beta blocker, (%) 0.039 2.156 3.497 0.6
Statin, (%) 0.081 1.268 3.836 0.3
Aspirin, (%) 0.253 1.569 6.729 0.002
ESA, (%) 0.03 2.424 3.506 0.7
Phosphate binders, (%) 0.134 8.063 0.748 0.1
Vitamin D analogs, (%) 0.067 4.899 2.028 0.4
OHA, (%) 0.125 7.127 0.913 0.1
Insulin, (%) 0.098 1.114 4.561 0.2
AST-120, (%) 0.096 1.246 4.881 0.2
BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure;
DM, Diabetes Mellitus; CAD, Coronary Artery Disease; Alb, Albumin; Cr, Creatinine;
eGFR, estimate Glomerular Filtration Rate; UA, Uric Acid; Ca, Calcium; P, Phosphate;
TC, Total Cholesterol; TG, Triglyceride; HDL-C, High Density Lipoprotein-
Cholesterol; LDL-C, Low Density Lipoprotein-Cholesterol; NHDL-C, non-High Den-
sity Lipoprotein-Cholesterol; BS, Blood Sugar; GA, GlycoAlbumin; CRP, C-Reactive
Protein; Hb, Hemoglobin; iPTH, intact Parathyroid Hormone; mCA-IMT, mean Ca-
rotid Artery-Intima Media Thickness; RASI, Renin Angiotensin System Inhibitor;
CCB, Calcium Channel Blocker; ESA, Erythropoiesis Stimulating Agent; OHA; Oral
Hypoglycemic Agent.
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stage kidney disease patients.
Alternatively, the results might be a consequence of differencesTable 4
Independent association of LDL-C with PS in multivariate linear regression analysis.
Model Adjustment
Model 1 Unadjusted
Model 2 Age, Male, Smoking, SBP, Era, DM, eGFR
Model 3 Model 2 þ Alb, CRP
Model 4 Model 2 þ TC, TG, HDL-C
Model 5 Model 2 þ Ca, P, iPTH, Vitamin D analogs, Phosphate binders
Model 6 Model 2 þ CAD, Stroke, RASI, Aspirin, Statin
Model 7 Model 2 þ Hb, ESA
Model 8 Model 2 þ HbA1c, OHA, Insulin
Model 9 Model 2 þ AST-120
SBP, Systolic Blood Pressure; DM, Diabetes Mellitus; eGFR, estimate Glomerular Filtration
Density Lipoprotein Cholesterol; Ca, Calcium; P, Phosphate; iPTH, intact Parathyroid Horm
Erythropoiesis Stimulating Agent; OHA, Oral Hypoglycemic Agent.in the methods used to measure the parameters. The PS has greater
scope for variation than the CA-IMT, and a large difference in the
values could produce a signiﬁcant difference. However, to produce
CA-IMT measurements with a small variation, a larger number of
patients may be necessary to conﬁrm the signiﬁcant difference.
Furthermore, changes in the numbers of plaques over the years
might have affected the differences in the changes in the CA-IMT
and the PS, although this was not evaluated during our study.
4.6. Statin usage in CKD
The 4D study [34] and AURORA study [35], which were ran-
domized, controlled trials involving dialysis patients, showed that
the overall risk of cardiovascular disease was not signiﬁcantly
decreased in patients given strong statins in the dialysis treatment
period. However, in the Study of Heart and Renal Protection
(SHARP) study [36] reported in 2011, a comparison was made be-
tween a simvastatin plus ezetimibe group and a placebo group in
9270 patients with CKD stage 3-5D, and the number of arterio-
sclerotic cardiovascular disease events was reduced signiﬁcantly,
by 17%. In a stratiﬁed analysis in the SHARP study, a signiﬁcant
decrease in risk of 20% was obtained in the non-dialysis group,
whereas the 10% decrease in the dialysis group was not signiﬁcant.
In a stratiﬁed analysis with pretreatment TC level, the decrease in
relative risk was signiﬁcantly greater with higher TC levels, nearly
the same as in the stratiﬁed analysis with the LDL-C level. Among
past large-scale, randomized, controlled trials using statins, sub-
analyses of subjects equivalent to CKD stage 3 [37e41] showed a
similar or larger decrease in relative risk of arteriosclerotic car-
diovascular disease as in non-CKD patients.
From the above, although a decreased risk of arteriosclerotic
cardiovascular disease with lipid-lowering therapy is also seen in
CKD patients, the size of the decrease in risk is not uniform. There is
thought to be a greater effect in early-stage CKD patients and pa-
tients with high pretreatment TC and LDL-C levels.
4.7. Limitations
The selection bias caused by only including those patients who
had undergone carotid artery ultrasonography was the biggest
limitation. Since this was a retrospective, observational study, the
sample size was small, with a total of 150 patients, and the number
of patients analyzed in Era 1 was particularly small. Therefore,
before the primary analysis, a preliminary analysis was performed
to determine the magnitude of the selection bias by comparing the
clinical characteristics of the groups that did and did not undergo
carotid artery ultrasonography. No sizeable differences were
detected in relation to the clinical characteristics between the
groups that did and did not undergo carotid artery ultrasonography
within the eras. Therefore, one can conclude that selection bias, ifRegression coefﬁcient 95% CI p r2
0.281 0.021 0.086 0.001 0.079
0.252 0.018 0.078 0.002 0.375
0.246 0.017 0.077 0.003 0.402
0.878 0.087 0.248 0.000 0.445
0.274 0.022 0.083 0.001 0.449
0.272 0.024 0.080 0.000 0.489
0.272 0.022 0.082 0.001 0.412
0.207 0.001 0.082 0.044 0.531
0.248 0.017 0.078 0.002 0.375
Rate; CRP, C-Reactive Protein; TC, Total Cholesterol; TG, Triglyceride; HDL-C, High
one; CAD, Coronary Artery Disease; RASI, Renin Angiotensin System Inhibitor; ESA,
Table 5
Comparison of baseline characteristics between the 150 ESKD patients with and without statin use for carotid artery atherosclerosis in 3 separate eras.
Era 1 Era 2 Era 3
Statin() Statin(þ) P Statin() Statin(þ) P Statin() Statin(þ) P
Total patients No. 26 8 32 13 33 38
Male, (%) 18(69) 6(75) 0.8 26(81) 13(100) 0.1 23(70) 24(63) 0.6
Age, year 66(55e74) 66(56e74) 0.6 70(59e79) 65(59e70) 0.2 77(64e83) 74(63e80) 0.3
TC, mg/dL 168(148e202) 146(125e208) 0.4 154(133e173) 151(125e206) 0.9 168(138e199) 150(124e169) 0.04
TG, mg/dL 112(87e154) 107(85e135) 0.8 94(72e112) 91(75e134) 0.9 104(85e139) 98(72e140) 0.7
HDL-C, mg/dL 48(40e56) 45(40e56) 0.9 45(36e55) 52(48e56) 0.08 46(38e66) 47(41e59) 0.9
LDL-C, mg/dL 107(87e125) 94(55e135) 0.4 91(68e112) 76(68e130) 0.9 96(76e126) 75(61e91) 0.02
NHDL-C, mg/dL 121(105e158) 101(74e151) 0.3 108(90e125) 95(81e154) 0.8 117(89e153) 96(74e116) 0.05
mCA-IMT, mm 0.7(0.6e0.9) 0.8(0.7e1.2) 0.1 0.9(0.7e1.1) 1.2(0.8e1.4) 0.3 0.9(0.7e1.1) 1.0(0.8e1.2) 0.05
PS 10.1(2.9e20.0) 17.9(10.1e26.0) 0.2 7.8(4.1e10.9) 11.5(6.7e15.1) 0.1 4.7(2.7e11.3) 6.1(4.0e13.3) 0.2
Data are means ± SD andmedians (interquartile range). TC, Total Cholesterol; TG, Triglyceride; HDL-C, High Density Lipoprotein-Cholesterol; LDL-C, Low Density Lipoprotein-
Cholesterol; NHDL-C, non-High Density Lipoprotein-Cholesterol; mCA-IMT, mean Carotid Artery-Intima Media Thickness; PS, Plaque Score.
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In addition, this was a cross-sectional comparative study of sepa-
rate eras; therefore, proving causal relationships between drug
administration or lipid value improvements and carotid athero-
sclerosis improvements was impossible. In this study, carotid artery
ultrasonography had been performed for 9 years, but instruments
and technicians changed during the period analyzed in this study.
However, we would like to emphasize that the instruments were
obtained from the same company, and that themeasurements were
performed by technicians trained by the same trainer. Since this
was a cross-sectional study, it was not possible to determine
whether the treatment periods related to the conservative phase of
kidney disease or to determine the speciﬁcs of the treatment, for
example, whether the statins were of conventional or of strong
type. In addition to the rate of statin use, the differences in the
efﬁcacies of the statins may be strongly associated with the
improvement in the PS. Given that this was a single-center, cross-
sectional study with a relatively small number of patients, a larger-
scale study should be undertaken in the future.
5. Conclusion
Carotid atherosclerosis in patients with ESKD has decreased
over the past 9 years. Changes in CKD management and patients'
characteristics in recent years have reduced LDL-C levels, which, in
turn, may have improved carotid atherosclerosis.
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